These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
437 related articles for article (PubMed ID: 26747242)
1. Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). Karlovich C; Goldman JW; Sun JM; Mann E; Sequist LV; Konopa K; Wen W; Angenendt P; Horn L; Spigel D; Soria JC; Solomon B; Camidge DR; Gadgeel S; Paweletz C; Wu L; Chien S; O'Donnell P; Matheny S; Despain D; Rolfe L; Raponi M; Allen AR; Park K; Wakelee H Clin Cancer Res; 2016 May; 22(10):2386-95. PubMed ID: 26747242 [TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875 [TBL] [Abstract][Full Text] [Related]
3. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259 [TBL] [Abstract][Full Text] [Related]
4. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study. Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929 [TBL] [Abstract][Full Text] [Related]
6. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor. Helman E; Nguyen M; Karlovich CA; Despain D; Choquette AK; Spira AI; Yu HA; Camidge DR; Harding TC; Lanman RB; Simmons AD Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111 [TBL] [Abstract][Full Text] [Related]
7. [3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance]. Brosseau S; Viala M; Varga A; Planchard D; Besse B; Soria JC Bull Cancer; 2015 Sep; 102(9):749-57. PubMed ID: 26235419 [TBL] [Abstract][Full Text] [Related]
8. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. Krug AK; Enderle D; Karlovich C; Priewasser T; Bentink S; Spiel A; Brinkmann K; Emenegger J; Grimm DG; Castellanos-Rizaldos E; Goldman JW; Sequist LV; Soria JC; Camidge DR; Gadgeel SM; Wakelee HA; Raponi M; Noerholm M; Skog J Ann Oncol; 2018 Mar; 29(3):700-706. PubMed ID: 29216356 [TBL] [Abstract][Full Text] [Related]
9. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198 [TBL] [Abstract][Full Text] [Related]
10. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors. Li C; Jia R; Liu H; Zhang B; Wang C Diagn Pathol; 2018 Aug; 13(1):49. PubMed ID: 30103780 [TBL] [Abstract][Full Text] [Related]
11. Lessons learned from routine, targeted assessment of liquid biopsies for Mondaca S; Offin M; Borsu L; Myers M; Josyula S; Makhnin A; Shen R; Riely GJ; Rudin CM; Ladanyi M; Yu HA; Li BT; Arcila ME Acta Oncol; 2019 Nov; 58(11):1634-1639. PubMed ID: 31347936 [No Abstract] [Full Text] [Related]
12. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor]. Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170 [No Abstract] [Full Text] [Related]
13. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. Wang S; Cang S; Liu D J Hematol Oncol; 2016 Apr; 9():34. PubMed ID: 27071706 [TBL] [Abstract][Full Text] [Related]
14. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy. Minari R; Bordi P; Del Re M; Facchinetti F; Mazzoni F; Barbieri F; Camerini A; Comin CE; Gnetti L; Azzoni C; Nizzoli R; Bortesi B; Rofi E; Petreni P; Campanini N; Rossi G; Danesi R; Tiseo M Lung Cancer; 2018 Jan; 115():21-27. PubMed ID: 29290257 [TBL] [Abstract][Full Text] [Related]
15. The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. Yoshimura A; Yamada T; Okura N; Takeda T; Furutani W; Kubota Y; Shiotsu S; Hiranuma O; Nishioka N; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K BMC Cancer; 2018 Dec; 18(1):1241. PubMed ID: 30537950 [TBL] [Abstract][Full Text] [Related]
16. EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits. Bencze E; Bogos K; Kohánka A; Báthory-Fülöp L; Sárosi V; Csernák E; Bittner N; Melegh Z; Tóth E Pathol Oncol Res; 2022; 28():1610607. PubMed ID: 36277960 [No Abstract] [Full Text] [Related]
17. Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib. Oya Y; Yoshida T; Asada K; Oguri T; Inui N; Morikawa S; Ito K; Kimura T; Kunii E; Matsui T; Kubo A; Kato T; Abe T; Tsuda T; Hida T BMC Cancer; 2021 Jan; 21(1):57. PubMed ID: 33435905 [TBL] [Abstract][Full Text] [Related]
18. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. Jenkins S; Yang JC; Jänne PA; Thress KS; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd FA J Thorac Oncol; 2017 Aug; 12(8):1247-1256. PubMed ID: 28527899 [TBL] [Abstract][Full Text] [Related]
19. Real-World Analysis of the Efficacy of Rebiopsy and Hong MH; Kim HR; Ahn BC; Heo SJ; Kim JH; Cho BC Yonsei Med J; 2019 Jun; 60(6):525-534. PubMed ID: 31124335 [TBL] [Abstract][Full Text] [Related]
20. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer. Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]